Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Sustained Complement C1s Inhibition with Sutimlimab in Patients with Cold Agglutinin Disease Results in Continued Efficacy during Part B of the Randomized Placebo-Controlled Phase 3 Cadenza Study (NCT03347422)

Blood (2022) 140 (Supplement 1): 2825–2827.

https://doi.org/10.1182/blood-2022-159562

Published: 2022

Journal Articles

Sutimlimab Provides Sustained Improvements in Patient-Reported Outcomes and Quality of Life in Patients with Cold Agglutinin Disease: Open-Label Extension of the Randomized, Phase 3 Cadenza Study

Alexander Roeth, Catherine M. Broome, Wilma Barcellini, Bernd Jilma, Quentin A. Hill, David Cella, Tor Henrik Anderson Tvedt, Masaki Yamaguchi, Irina Murakhovskaya, Michelle Lee, Frank Shafer, Marek Wardecki, Jennifer Wang, Ronnie Yoo, Jerome Mshijid, Ilene C. Weitz

Blood (2022) 140 (Supplement 1): 70–72.

https://doi.org/10.1182/blood-2022-159966

Published: 2022

Journal Articles

Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial

Alexander Röth, Sigbjørn Berentsen, Wilma Barcellini, Shirley D’Sa, Bernd Jilma, Marc Michel, Ilene C. Weitz, Masaki Yamaguchi, Jun-ichi Nishimura, Josephine M. I. Vos, Michael Storek, Nancy Wong, Parija Patel, Xiaoyu Jiang, Deepthi S. Vagge, Marek Wardęcki, Frank Shafer, Michelle Lee, Catherine M. Broome

Blood (2022) 140 (9): 980–991.

https://doi.org/10.1182/blood.2021014955

Published: 2022

Includes: Supplemental data

Journal Articles

Online CME As a Tool to Increase Clinicians' Ability to Identify and Diagnose Paroxysmal Nocturnal Hemoglobinuria

Michelle Arielle Worst, Emily S. Van Laar, Lisa A Cockrell, Ilene C. Weitz

Blood (2021) 138 (Supplement 1): 2988.

https://doi.org/10.1182/blood-2021-145660

Published: 2021

Journal Articles

Evaluation of the Long-Term Safety and Efficacy of Pegcetacoplan Treatment for Paroxysmal Nocturnal Hemoglobinuria Patients: An Extension Study

Kate Hoffman, Zurab Machaidze, Michael Yeh, Ilene C. Weitz

Blood (2021) 138 (Supplement 1): 2175.

https://doi.org/10.1182/blood-2021-148042

Published: 2021

Journal Articles

Inhibition of Complement C1s By Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Efficacy and Safety Results from the Randomized, Placebo-Controlled Phase 3 CADENZA Study

Blood (2021) 138 (Supplement 1): 349.

https://doi.org/10.1182/blood-2021-148066

Published: 2021

Journal Articles

Categorized Hematologic Response to Pegcetacoplan Versus Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Post Hoc Analysis of Data from a Phase 3 Randomized Trial (PEGASUS)

Antonio Risitano, Ilene C. Weitz, Carlos M. de Castro, MD, Jean-Jacques Kiladjian, Morag Griffin, MBChB, FRCPath, Hisakazu Nishimori, MD PhD, Mohamed Hamdani, Temitayo Ajayi, Scott B. Baver, PhD, Regis Peffault De Latour, MD PhD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-142166

Published: 2020

Journal Articles

Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria

Peter Hillmen, MBChB, PhD, Jeffrey Szer, MBBS, Ilene C. Weitz, Alexander Röth, MD, Britta Hoechsmann, Jens Panse, MD, Kensuke Usuki, MD PhD, Morag Griffin, MBChB, FRCPath, Jean-Jacques Kiladjian, MD PhD, Carlos M. de Castro, MD, Hisakazu Nishimori, MD PhD, Lisa Tan, Mohamed Hamdani, Pascal Deschatelets, PhD, Cedric Francois, MD PhD, Federico Grossi, MD, Antonio Risitano, Regis Peffault De Latour, MD PhD

Blood (2020) 136 (Supplement 1): 35–37.

https://doi.org/10.1182/blood-2020-142174

Published: 2020

Journal Articles

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Interim Results of the Phase 3 Cardinal Study Long-Term Follow-up

Alexander Röth, MD, Wilma Barcellini, Shirley D'Sa, Yoshitaka Miyakawa, Catherine M Broome, Marc Michel, David J. Kuter, MD, Bernd Jilma, Tor Henrik Anderson Tvedt, Ilene C. Weitz, Parija Patel, Xiaoyu Jiang, Caroline Reuter, Jun Su, Frank Shafer, Michelle Lee, William Hobbs, Sigbjørn Berentsen

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-138909

Published: 2020

Journal Articles

Pegcetacoplan Is Superior to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Regardless of Prior Transfusion Requirement

Regis Peffault De Latour, MD PhD, Carlos M. de Castro, MD, Jeffrey Szer, MBBS, Kensuke Usuki, MD PhD, Peter Hillmen, MBChB, PhD, Morag Griffin, MBChB, FRCPath, Mohamed Hamdani, MS, Temitayo Ajayi, Hisakazu Nishimori, MD PhD, Ilene C. Weitz

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-141061

Published: 2020

Journal Articles

Inflammation and Fatigue in Patients with Cold Agglutinin Disease (CAD): Analysis from the Phase 3 Cardinal Study

Ilene C. Weitz, Yasutaka Ueda, Frank Shafer, Jun Su, Meredith Foster, Michael Storek, Parija Patel

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-140335

Published: 2020

Journal Articles

A Prospective Analysis of Breakthrough Hemolysis in 2 Phase 3 Randomized Studies of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria

Robert A. Brodsky, MD, Regis Peffault De Latour, Scott T. Rottinghaus, MD, Alexander Röth, MD, Antonio M. Risitano, MD PhD, Ilene C. Weitz, MD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Jaroslaw P. Maciejewski, Jeffrey Szer, MBBS, Jong-Wook Lee, MD PhD, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Lori Volles, MD, Andrew I. Damokosh, PhD, Stephan Ortiz, RPh, PhD, Lori Shafner, PhD, Anita Hill, MD PhS, Hubert Schrezenmeier, MD

Blood (2018) 132 (Supplement 1): 2330.

https://doi.org/10.1182/blood-2018-99-110874

Published: 2018

Journal Articles

A Phase 3 Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria Naive to Complement Inhibitors: Results of a Subgroup Analysis with Patients Stratified By Baseline Hemolysis Level, Transfusion History, and Demographics

Ilene C. Weitz, MD, Aleksandr Kulagin, Shinji Nakao, MD PhD, Caroline I. Piatek, MD, Jeffrey Szer, MBBS, Scott T. Rottinghaus, MD, Lori Volles, MD, Andrew I. Damokosh, PhD, Rasha Aguzzi, MS, Loree Larratt, MD, Antonio M. Risitano, MD PhD

Blood (2018) 132 (Supplement 1): 627.

https://doi.org/10.1182/blood-2018-99-110623

Published: 2018

Journal Articles

Eculizumab Treatment Improves Outcomes of Pregnancy in Patients with Paroxysmal Nocturnal Hemoglobinuria

Richard J Kelly, MBChB, PhD, Britta Höchsmann, MD, Austin Kulasekararaj, Sophie de Guibert, MD, Alexander Röth, MD, Ilene C Weitz, MD, Elina Armstrong, MD PhD, Anita Hill, MBChB, PhD, Antonio M. Risitano, MD PhD, Christopher J Patriquin, MDFRCPC, Louis Terriou, MD, Petra Muus, MD PhD, Michelle P Turner, MS in Biostatistics, Hubert Schrezenmeier, MD PhD, Jeffrey Szer, MB BS FRACP, Regis Peffault de Latour, MD PhD

Blood (2014) 124 (21): 4393.

https://doi.org/10.1182/blood.V124.21.4393.4393

Published: 2014

Journal Articles

Life-Threatening Delayed Hemolytic Transfusion Reaction in a Patient with Sickle Cell Disease: Effective Treatment with Eculizumab Followed By Rituximab

Ilene C Weitz, MD, Mark Boonyasampant, MD, Brian Kay, MD, Chaiyaporn Boonchalervichian, MD, Howard A. Liebman, MA, MD, Ira A. Shulman, MD

Blood (2014) 124 (21): 4286.

https://doi.org/10.1182/blood.V124.21.4286.4286

Published: 2014

Journal Articles

Ethnic and Racial Difference In H.Pylori Infection In Patients With ITP Treated At A MAJOR Tertiary Medical Center In LOS Angeles

Caitlin M O'Neill, BA, Ulysses Gomez, BA, Ilene C Weitz, MD, Casey O'Connell, MD, Howard Liebman, MD

Blood (2013) 122 (21): 3548.

https://doi.org/10.1182/blood.V122.21.3548.3548

Published: 2013

Journal Articles

Romiplostim For Thrombocytopenia in Patients with Hepatitis C (HCV)-Associated Liver Disease: Preliminary Report Of An Ongoing Clinical Trial

Howard Liebman, MD, Laurie Hornor, BA, Tse-Ling Fong, MD, Casey O'Connell, MD, Ilene C Weitz, MD

Blood (2013) 122 (21): 3555.

https://doi.org/10.1182/blood.V122.21.3555.3555

Published: 2013

Journal Articles

A Novel Hybrid CFH/CFHR1–3 Gene in Atypical Hemolytic Uremic Syndrome

Mehmet F. Hepgur, MD, Preeti Chaudhary, MD, Sarmen Sarkissian, MD, Richard J. H. Smith, MD, Howard Liebman, MD, Ilene C Weitz, MD

Blood (2012) 120 (21): 4644.

https://doi.org/10.1182/blood.V120.21.4644.4644

Published: 2012

Journal Articles

Incidence of PNH Clones by Diagnostic Code Utilizing High Sensitivity Flow Cytometry

Mayur K Movalia, M.D., Ilene c Weitz, MD, Seah H Lim, MD, PhD, Andrea Illingworth

Blood (2011) 118 (21): 1033.

https://doi.org/10.1182/blood.V118.21.1033.1033

Published: 2011

Journal Articles

Tinzaparin Is Effective and Safe for the Treatment and Extended Secondary Prophylaxis In Cancer Patients with Venous Thromboembolism.

Scott T Tagawa, MD, Ilene c Weitz, MD, Casey L. O'Connell, MD, Leanne Rochanda, MS, Mckenna Archer, David I Quinn, MD, PhD, Howard Liebman, MD

Blood (2010) 116 (21): 1104.

https://doi.org/10.1182/blood.V116.21.1104.1104

Published: 2010

NARROW

Sustained Complement C1s Inhibition with Sutimlimab in Patients with Cold Agglutinin Disease Results in Continued Efficacy during Part B of the Randomized Placebo-Controlled Phase 3 Cadenza Study (NCT03347422)

Sutimlimab Provides Sustained Improvements in Patient-Reported Outcomes and Quality of Life in Patients with Cold Agglutinin Disease: Open-Label Extension of the Randomized, Phase 3 Cadenza Study

Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial

Online CME As a Tool to Increase Clinicians' Ability to Identify and Diagnose Paroxysmal Nocturnal Hemoglobinuria

Evaluation of the Long-Term Safety and Efficacy of Pegcetacoplan Treatment for Paroxysmal Nocturnal Hemoglobinuria Patients: An Extension Study

Inhibition of Complement C1s By Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Efficacy and Safety Results from the Randomized, Placebo-Controlled Phase 3 CADENZA Study

Categorized Hematologic Response to Pegcetacoplan Versus Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Post Hoc Analysis of Data from a Phase 3 Randomized Trial (PEGASUS)

Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Interim Results of the Phase 3 Cardinal Study Long-Term Follow-up

Pegcetacoplan Is Superior to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Regardless of Prior Transfusion Requirement

Inflammation and Fatigue in Patients with Cold Agglutinin Disease (CAD): Analysis from the Phase 3 Cardinal Study

A Prospective Analysis of Breakthrough Hemolysis in 2 Phase 3 Randomized Studies of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria

A Phase 3 Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria Naive to Complement Inhibitors: Results of a Subgroup Analysis with Patients Stratified By Baseline Hemolysis Level, Transfusion History, and Demographics

Eculizumab Treatment Improves Outcomes of Pregnancy in Patients with Paroxysmal Nocturnal Hemoglobinuria

Life-Threatening Delayed Hemolytic Transfusion Reaction in a Patient with Sickle Cell Disease: Effective Treatment with Eculizumab Followed By Rituximab

Ethnic and Racial Difference In H.Pylori Infection In Patients With ITP Treated At A MAJOR Tertiary Medical Center In LOS Angeles

Romiplostim For Thrombocytopenia in Patients with Hepatitis C (HCV)-Associated Liver Disease: Preliminary Report Of An Ongoing Clinical Trial

A Novel Hybrid CFH/CFHR1–3 Gene in Atypical Hemolytic Uremic Syndrome

Incidence of PNH Clones by Diagnostic Code Utilizing High Sensitivity Flow Cytometry

Tinzaparin Is Effective and Safe for the Treatment and Extended Secondary Prophylaxis In Cancer Patients with Venous Thromboembolism.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only